Industry Focus
Healthcare: Alkermes Super-Bad Day, and Illumina's Surprising M&A News
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:26:35
- Mas informaciones
Informações:
Sinopsis
Why Alkermes once-promising depression drug failed to impress the FDA's advisory committee. Plus, how a $1.2 billion acquisition of Pacific Biosciences could move the needle at Illumina. Stocks: ALKS, ILMN, PACB
